Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Inflammatory Bowel Diseases

  Free Subscription


07.04.2020

15 Aliment Pharmacol Ther
2 Am J Gastroenterol
7 Clin Gastroenterol Hepatol
4 Dig Dis Sci
1 Gastroenterology
1 Gut
10 Inflamm Bowel Dis
6 J Crohns Colitis
1 Lancet Gastroenterol Hepatol
1 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. IBORRA M, Beltran B, Nos P
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:600-601.
    PubMed        

  2. MUSGROVE J, Wolf M
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia.
    Aliment Pharmacol Ther. 2019;50:609-610.
    PubMed        

  3. SEOW CH, Targownik LE
    Editorial: understanding sex and gender dimorphism in chronic diseases may improve outcomes.
    Aliment Pharmacol Ther. 2019;50:603-604.
    PubMed        

  4. DETLIE TE, Jahnsen J
    Editorial: awareness and prevention of intravenous iron-induced hypophosphataemia. Authors' reply.
    Aliment Pharmacol Ther. 2019;50:610-611.
    PubMed        

  5. FRASCA JD, Cheifetz AS
    Editorial: real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease-results from the ENEIDA registry.
    Aliment Pharmacol Ther. 2019;50:599-600.
    PubMed        

  6. SCHREINER P, Biedermann L
    Editorial: anti-TNF therapy-a double-edged sword?
    Aliment Pharmacol Ther. 2019;50:822-823.
    PubMed        

  7. KORZENIK J, Larsen MD, Nielsen J, Kjeldsen J, et al
    Editorial: anti-TNF therapy-a double-edged sword? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:823-824.
    PubMed        

  8. ASHTON JJ, Beattie RM
    Letter: anti-TNF therapy and intestinal resections in Crohn's disease-are we just delaying the inevitable?
    Aliment Pharmacol Ther. 2019;50:842-843.
    PubMed        

  9. WALL CL, Day AS
    Editorial: the reduction of faecal calprotectin during exclusive enteral nutrition is lost rapidly after food reintroduction.
    Aliment Pharmacol Ther. 2019;50:824-825.
    PubMed        

  10. BIEMANS VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, et al
    Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15689.
    PubMed         Abstract available

  11. KING D, Reulen RC, Thomas T, Chandan JS, et al
    Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018.
    Aliment Pharmacol Ther. 2020 Apr 1. doi: 10.1111/apt.15701.
    PubMed         Abstract available

  12. LAURIOT DIT PREVOST C, Azahaf M, Nachury M, Branche J, et al
    Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lemann Index and Inflammatory Bowel Disease Disability Index.
    Aliment Pharmacol Ther. 2020 Mar 27. doi: 10.1111/apt.15681.
    PubMed         Abstract available

  13. MENON S, Bressler B
    Editorial: aminosalicylates and nephrotoxicity-an issue put to rest.
    Aliment Pharmacol Ther. 2019;50:1059.
    PubMed        

  14. LIN YS, Chen MJ, Lin WC, Wang YH, et al
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? Authors' reply.
    Aliment Pharmacol Ther. 2019;50:970-971.
    PubMed        

  15. YAMAMOTO T, Kotze PG
    Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?
    Aliment Pharmacol Ther. 2019;50:969-970.
    PubMed        


    Am J Gastroenterol

  16. LIMDI JK
    Continuing Medical Education Questions: April 2020: Men with Inflammatory Bowel Disease: Sexual Function, Fertility, Medication Safety, and Prostate Cancer.
    Am J Gastroenterol. 2020;115:506.
    PubMed        

  17. BOOTH AT, Forster E, Curran T, George V, et al
    Gastrocolic Fistula Involving the Pancreas in a Patient With Crohn's Disease.
    Am J Gastroenterol. 2019;114:1823-1824.
    PubMed        


    Clin Gastroenterol Hepatol

  18. CHRISTENSEN B, Gibson PR, Micic D, Colman RJ, et al
    Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2019;17:486-493.
    PubMed         Abstract available

  19. COLOMBEL JF, Shin A, Gibson PR
    AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review.
    Clin Gastroenterol Hepatol. 2019;17:380-390.
    PubMed         Abstract available

  20. BEAUGERIE L, Kirchgesner J
    Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2019;17:370-379.
    PubMed         Abstract available

  21. NALAGATLA N, Falloon K, Tran G, Borren NZ, et al
    Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis.
    Clin Gastroenterol Hepatol. 2019;17:502-509.
    PubMed         Abstract available

  22. NARULA N, Alshahrani AA, Yuan Y, Reinisch W, et al
    Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2019;17:411-418.
    PubMed         Abstract available

  23. SIMSEK M, Meijer B, Ramsoekh D, Bouma G, et al
    Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Clin Gastroenterol Hepatol. 2019;17:568-570.
    PubMed         Abstract available

  24. MUIR AJ
    What Clues Can We Use From Primary Sclerosing Cholangitis With Inflammatory Bowel Disease Phenotypes?
    Clin Gastroenterol Hepatol. 2020 Mar 30. pii: S1542-3565(20)30430.
    PubMed        


    Dig Dis Sci

  25. VAN ERP LW, Roosenboom B, Komdeur P, Dijkstra-Heida W, et al
    Improvement of Fatigue and Quality of Life in Patients with Quiescent Inflammatory Bowel Disease Following a Personalized Exercise Program.
    Dig Dis Sci. 2020 Apr 1. pii: 10.1007/s10620-020-06222.
    PubMed         Abstract available

  26. LONGHI MS, Kokkotou E
    Lnc-ing RNA Expression with Disease Pathogenesis: MALAT1 and ANRIL in Ulcerative Colitis.
    Dig Dis Sci. 2020 Mar 30. pii: 10.1007/s10620-020-06216.
    PubMed        

  27. LEE JS, Lee HS, Jang BI, Kim ES, et al
    Low Bone Mineral Density in Young Patients Newly Diagnosed with Inflammatory Bowel Disease.
    Dig Dis Sci. 2020 Mar 28. pii: 10.1007/s10620-020-06220.
    PubMed         Abstract available

  28. HAM NS, Hwang SW, Oh EH, Kim J, et al
    Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease.
    Dig Dis Sci. 2020 Mar 26. pii: 10.1007/s10620-020-06207.
    PubMed         Abstract available


    Gastroenterology


  29. Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.
    Gastroenterology. 2020;158:1462-1463.
    PubMed        


    Gut

  30. FAIRBRASS KM, Hoshen D, Gracie DJ, Ford AC, et al
    Effect of ACE inhibitors and angiotensin II receptor blockers on disease outcomes in inflammatory bowel disease.
    Gut. 2020 Apr 2. pii: gutjnl-2020-321186. doi: 10.1136/gutjnl-2020-321186.
    PubMed        


    Inflamm Bowel Dis

  31. LIGHTNER AL, Alsughayer A, Wang Z, McKenna NP, et al
    Short- and Long-term Outcomes After Ileal Pouch Anal Anastomosis in Pediatric Patients: A Systematic Review.
    Inflamm Bowel Dis. 2019;25:1152-1168.
    PubMed         Abstract available

  32. BERTANI L, Rossari F, Barberio B, Demarzo MG, et al
    Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio.
    Inflamm Bowel Dis. 2020 Mar 31. pii: 5813970. doi: 10.1093.
    PubMed         Abstract available

  33. GARCIA GARCIA MJ, Rivero Tirado M, Callizo MEP
    Paradoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.
    Inflamm Bowel Dis. 2019;25:e89.
    PubMed        

  34. GROSSBERG LB
    A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab.
    Inflamm Bowel Dis. 2019;25:e84.
    PubMed        

  35. SIMONS-LINARES CR, Chahal P
    Successful EUS-guided Drainage of a Persistent Subdiaphragmatic Fluid Collection in a Patient With Crohn's Disease.
    Inflamm Bowel Dis. 2019;25:e85-e86.
    PubMed        

  36. KURIN M, Katz J, Kodish E, Lashner B, et al
    Informed Consent in IBD Trials: Where We Are and Where We Need to Go.
    Inflamm Bowel Dis. 2019;25:1115-1119.
    PubMed         Abstract available

  37. PATEL P, Gao G, Gulotta G, Dalal S, et al
    Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2020 Mar 27. pii: 5812729. doi: 10.1093.
    PubMed         Abstract available

  38. EVERHOV AH, Khalili H, Askling J, Myrelid P, et al
    Work Loss Before and After Diagnosis of Crohn's Disease.
    Inflamm Bowel Dis. 2019;25:1237-1247.
    PubMed         Abstract available

  39. ZHAO M, Lo BZS, Vester-Andersen MK, Vind I, et al
    A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort.
    Inflamm Bowel Dis. 2019;25:1227-1236.
    PubMed         Abstract available

  40. KRISHNAKUMAR C, Ballengee CR, Liu C, Kim MO, et al
    Variation in Care in the Management of Children With Crohn's Disease: Data From a Multicenter Inception Cohort Study.
    Inflamm Bowel Dis. 2019;25:1208-1217.
    PubMed         Abstract available


    J Crohns Colitis

  41. LIEFFERINCKX C, Verstockt B, Gils A, Noman M, et al
    Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    J Crohns Colitis. 2019;13:1401-1409.
    PubMed         Abstract available

  42. MOHAMMADI A, Kelly OB, Smith MI, Kabakchiev B, et al
    Differential miRNA Expression in Ileal and Colonic Tissues Reveals an Altered Immunoregulatory Molecular Profile in Individuals With Crohn's Disease versus Healthy Subjects.
    J Crohns Colitis. 2019;13:1459-1469.
    PubMed         Abstract available

  43. KLAASSEN MAY, Imhann F, Collij V, Fu J, et al
    Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations.
    J Crohns Colitis. 2019;13:1439-1449.
    PubMed         Abstract available

  44. SMEETS FGM, Liedorp PR, van der Poel M, Miclea RL, et al
    Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.
    J Crohns Colitis. 2019;13:1470-1473.
    PubMed         Abstract available

  45. MONTELEONE G, Ardizzone S
    Are patients with inflammatory bowel disease at increased risk for Covid-19 infection?
    J Crohns Colitis. 2020 Mar 26. pii: 5811674. doi: 10.1093.
    PubMed         Abstract available

  46. BAI X, Yang H, Qian J
    COVID-19 outbreak and inflammatory bowel disease management: a questionnaire survey from realistic practice.
    J Crohns Colitis. 2020 Mar 28. pii: 5812999. doi: 10.1093.
    PubMed        


    Lancet Gastroenterol Hepatol

  47. ZINGONE F, Savarino EV
    Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.
    Lancet Gastroenterol Hepatol. 2020 Mar 25. pii: S2468-1253(20)30085.
    PubMed        


    PLoS One

  48. COOPE A, Pascoal LB, Botezelli JD, da Silva FAR, et al
    ER stress activation in the intestinal mucosa but not in mesenteric adipose tissue is associated with inflammation in Crohn's disease patients.
    PLoS One. 2019;14:e0223105.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  49. JANG SW, Hwang SS, Kim HS, Kim MK, et al
    Homeobox protein Hhex negatively regulates Treg cells by inhibiting Foxp3 expression and function.
    Proc Natl Acad Sci U S A. 2019;116:25790-25799.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: